Poster

Targeted Optimization Of An Upstream AAV8 Process For Enhanced Downstream Performance

Source: Sartorius

By Petra Dekleva, Ivana Petrović Koshmak, Janja Merkelj Koren, Rok Žigon, Andrej Mihevc, Mirjam Krašna, Kaja Bažec, Valentina Novak, Marko Šnajder, Sandra Potušek, Maja Leskovec, and Aleš Štrancar

Adeno-associated viruses AAV GettyImages-1322096218

While several recombinant adeno-associated viral vector (rAAV)-mediated therapies have received approval, and many more are undergoing clinical trials, establishing an efficient rAAV process platform remains a significant hurdle. One primary challenge stems from the frequent practice of developing upstream (USP) and downstream (DSP) processes separately. USP optimization activities often prioritize achieving a high viral titer, which may not always result in maximal purity and recovery during DSP.

A second obstacle is the lack of suitable analytical methodology capable of delivering the reliable and unbiased results essential for integrating USP and DSP into a single bioprocess. Additionally, rAAV-based gene therapy vectors necessitate the elimination of both process- and product-specific impurities, as these can pose serious safety risks.

Here, we show an example of AAV8 USP optimization directed towards enhancing DSP performance where AAV8 is generated in HEK293 suspension cells through plasmid transfection.

access the Poster!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Pharmaceutical Online